[1]邓仁麑,何静,刘奉凤,等.重庆市新确证HIV-1感染者传播性耐药突变研究[J].第三军医大学学报,2018,40(03):270-274.
 DENG Renni,HE Jing,LIU Fengfeng,et al.Surveillance of HIV-1 transmitted drug resistance mutation among newly diagnosed HIV-1 individuals in Chongqing[J].J Third Mil Med Univ,2018,40(03):270-274.
点击复制

重庆市新确证HIV-1感染者传播性耐药突变研究(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
40卷
期数:
2018年第03期
页码:
270-274
栏目:
公共卫生与预防医学
出版日期:
2018-02-15

文章信息/Info

Title:
Surveillance of HIV-1 transmitted drug resistance mutation among newly diagnosed HIV-1 individuals in Chongqing
作者:
邓仁麑何静刘奉凤李俊刚李清华王静
重庆市公共卫生医疗救治中心
Author(s):
DENG Renni HE Jing LIU Fengfeng LI Jungang LI Qinghua WANG Jing

Chongqing Infectious Disease Medical Center, Chongqing, 400036, China

关键词:
人类免疫缺陷病毒1型新确证未治疗传播性耐药突变
Keywords:
HIV-1 newly diagnosed treatment-naive transmitted drug resistance mutations
分类号:
R394.6; R512.91; R915
文献标志码:
A
摘要:

目的     通过对重庆市新确证人类免疫缺陷病毒1型(HIV-1)感染者耐药基因型的研究,了解我市耐药病毒株的传播水平。方法     采集2014年5月至2017年6月我院新确证未治疗的HIV-1感染者的外周血175例,分离血浆后,使用一步法RT-PCR和巢式PCR扩增HIV-1pol区的基因,PCR产物经纯化后测序,将获得的基因序列与美国雅培公司的耐药数据库对比,得出患者对药物的耐药性解释。结果    PCR扩增阳性且测序成功168例,发现16例患者存在耐药突变,传播性耐药突变检出率达 9.5%(16/168),其中2014-2017年的耐药比例分别为7.0%、8.0%、9.1%、12.5%,属中度流行。非核苷类反转录酶抑制剂(NNRTIs)、核苷类反转录酶抑制剂(NRTIs)和蛋白酶抑制剂(PIs)耐药突变率分别为9.5%、2.4%和0%。V179D/E(7.1%)和M184V(2.4%)分别是出现最多的NNRTI和NRTI耐药突变位点。168例感染者中,CRF07_BC亚型是主要流行亚型(42.8%),其次为CRF01_AE(38.7%)和CRF08_BC亚型(10.1%)。结论     重庆市新确证未治疗HIV-1感染者耐药比例有逐年上升的趋势,应加强监测,预防原发性耐药和耐药毒株的传播。

Abstract:

Objective     To investigate the prevalence of HIV-1 drug-resistant strains by exploring the genotypes of the resistance genes in newly diagnosed HIV type1-infected patients in Chongqing city. Methods     Plasma specimens of 175 newly diagnosed and antiretroviral treatment-naive HIV-1 infected patients were collected from our center during May 2014 to June 2017. After plasma and serum separation, one-step RT-PCR and nested PCR were taken to amplify the pol gene, then PCR products were sequenced after purification, and the obtained nucleotide sequences were compared with resistance database of the United States Abbott to acquire the interpretation of drug resistance. Results     A total of 168 samples were successfully amplified and sequenced. Sixteen patients were found with drug resistant mutations. The total prevalence of transmitted antiretroviral drug resistance (TDR) was 9.5%, and the drug resistance rate was 7.0%, 8.0%, 9.1% and 12.5% respectively in the years of 2014 to 2017, which was classified as moderate. The resistance mutation rates of non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs) were 9.5%, 2.4% and 0%, respectively. V179D/E (7.1%) and M184V (2.4%) were the most commonly emerged NNRTI and NRTI resistance mutations. Among the 168 patients, CRF07_BC was the predominant subtype, accounting for 42.8%, followed by CRF01_AE (38.7%) and CRF07_ BC (10.1%). Conclusion     The rate of TDR  is increasing year by year among newly diagnosed, antiretroviral treatment-naive patients in Chongqing city. So it is necessary to do HIV-1 resistance genotyping test for those patients.

参考文献/References:

[1]中国疾病预防控制中心, 性病艾滋病预防控制中心, 性病控制中心. 2016年10月全国艾滋病性病疫情[J]. 中国艾滋病性病, 2016,12(22): 945.DOI: 10.13419/j.cnki.aids.2016.12.01.
NCAIDS, NCSTD, China CDC. Update on the AIDS/STD epidemic in China in October,2016 [J]. Chin J AIDS STD, 2016,12(22): 945.DOI: 10.13419/j.cnki.aids.2016.12.01.
[2]ZHANG F, DOU Z, MA Y, et al. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIVrelated mortality in China: a national observational cohort study[J]. Lancet Infect Dis, 2011, 11(7): 516-524. DOI:10.1016/s14733099(11)700974.
[3]LIAO L, XING H, SU B, et al. Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China[J]. Aids, 2013, 27(11): 1815-1824. DOI:10.1097/qad.0b013e3283611931.
[4]左中宝, 邢辉. 抗病毒治疗患者HIV耐药发生的研究进展[J]. 传染病信息, 2015, 28(6): 348-351. DOI:10.3969/j.issn.10078134.2015.06.004.
ZUO Z B, XING H. Research advances in HIV drug resistance among patients receiving antiretroviral treatment[J]. Infect Dis Info, 2015, 28(6): 348-351. DOI:10.3969/j.issn.10078134.2015.06.004.
[5]周全华, 凌华, 邢辉, 等. 重庆市HIV1耐药警戒线调查[J]. 现代预防医学, 2013, 40(20): 3860-3862,3864.
ZHOU Q H, LING H, XING H, et al. Survey on the drug resistance threshold of HIV1 in Chongqing [J]. Mod Prevent Med, 2013, 40(20): 3860-3862,3864.
[6]WHO. Draft guidelines for surveillance of HIV drug resistance. Executive Summary [EB/OL]. [20170914]. http://www.who.int/3by5/publications/guidelines/en/execsumm.pdf.
[7]周海卫. 我国流行的主要HIV1亚型耐药基因特征及不同耐药数据库系统分析[D]. 北京:中国疾病预防控制中心, 2008.
ZHOU H W. Analysis of resistanceassociated genetic characteristic from subtype B, CRF01_AE and CRF07_BC isolates prevailing in China [D]. Beijing: China Center Disease Control Prevention, 2008.
[8]HE X, XING H, RUAN Y, et al. A comprehensive mapping of HIV1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey[J]. PLoS ONE, 2012, 7(10): e47289. DOI:10.1371/journal.pone.0047289.
[9]WENSING A M, VAN DE VIJVER D A, ANGARANO G, et al. Prevalence of drugresistant HIV1 variants in untreated individuals in Europe: implications for clinical management[J]. J Infect Dis, 2005, 192(6): 958-966. DOI:10.1086/432916.
[10]ROSS L, LIM M L, LIAO Q, et al. Prevalence of antiretroviral drug resistance and resistanceassociated mutations in antiretroviral therapynave HIVinfected individuals from 40 United States cities[J]. HIV Clin Trials, 2007, 8(1): 1-8. DOI:10.1310/hct08011.
[11]张莉, 黄伟忠, 陈先辉. 深圳地区新近诊断HIV1感染者的传播耐药性检测[J]. 海南医学院学报, 2012, 18(8): 1140-1143,1148.
ZHANG L, HUANG W Z, CHEN X H. Transmitted antiretroviral drug resistance among newly diagnosed HIV1 individualsin Shenzhen[J]. J Hainan Med Univ, 2012, 18(8): 1140-1143,1148.
[12]北京市疾病预防控制中心. 2016年北京市艾滋病疫情通报[EB/OL]. [20170905].http://www.bjcdc.org/article/43037/2016/12/1480574106480.html.
Beijing Center for Disease Control and Prevention. Update on the AIDS Epidemic in Beijing in 2016 [EB/OL]. [20170905].http://www.bjcdc.org/article/43037/2016/12/1480574106480.html.
[13]CLAVEL F, HANCE A J. HIV drug resistance[J]. N Engl J Med, 2004, 350(10): 1023-1035. DOI:10.1056/NEJMra025195.
[14]COZZILEPRI A, PHILLIPS A N, CLOTET B, et al. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study[J]. AIDS, 2008, 22(16): 2187-2198. DOI:10.1097/QAD.0b013e328310e04f.
[15]XING H, WANG X, LIAO L, et al. Incidence and associated factors of HIV drug resistance in Chinese HIVinfected patients receiving antiretroviral treatment[J]. PLoS ONE, 2013, 8(4): e62408. DOI:10.1371/journal.pone.0062408.
[16]TEERANAIPONG P, SIRIVICHAYAKUL S, MEKPRASAN S, et al. Rilpivirine versus etravirine validity in NNRTIbased treatment failure in Thailand[J]. J Int AIDS Soc, 2014, 17(4 Suppl 3): 19740.
[17]CHAPLIN B, EISEN G, IDOKO J, et al. Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing firstline therapy[J]. AIDS Res Hum Retroviruses,2011,27(1):71-80. DOI:10.1089/aid.2010.0050.
[18]MITSUYA Y, VARGHESE V, WANG C, et al. Minority human immunodeficiency virus type 1 variants in antiretroviralnaive persons with reverse transcriptase codon 215 revertant mutations[J]. J Virol, 2008, 82(21): 10747-10755. DOI:10.1128/JVI.0182707.
[19]BARENNES H, GUILLET S, LIMSRENG S, et al. Virological failure and HIV1 drug resistance mutations among naive and antiretroviral pretreated patients entering the ESTHER program of Calmette Hospital in Cambodia[J]. PLoS ONE, 2014, 9(8): e105736. DOI:10.1371/journal.pone.0105736.
[20]SSEMWANGA D, LIHANA R W, UGOJI C, et al. Update on HIV1 acquired and transmitted drug resistance in Africa[J]. AIDS Rev, 2015, 17(1): 3-20.
[21]HAMERS R L, SIGALOFF K C, WENSING A M, et al. Patterns of HIV1 drug resistance after firstline antiretroviral therapy (ART) failure in 6 subSaharan African countries: implications for secondline ART strategies[J]. Clin Infect Dis, 2012, 54(11): 1660-1669. DOI:10.1093/cid/cis254.
[22]WHITE K L, CHEN J M, MARGOT N A, et al. Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analogassociated mutations[J]. Antimicrob Agents Chemotherap, 2004, 48(3): 992-1003. DOI:10.1128/aac.48.3.9921003.2004.

更新日期/Last Update: 2018-02-13